Efficacy of a Structured Weight Loss Program in Overweight Women With a History of Recurrent Pregnancy Loss
Overweight and obesity has been associated with a number of adverse pregnancy outcomes in women of reproductive age, including infertility and early pregnancy loss. Recent data suggests that overweight and obese patients are also at increased risk of recurrent pregnancy loss (RPL), a devastating condition that affects 1% of the fertile population.
The investigators propose a prospective, randomized controlled trial in which overweight and obese patients with unexplained recurrent pregnancy loss are enrolled in a structured, 6 month, weight loss program or provided routine counseling regarding the importance of weight loss. Pregnancy outcomes will then be followed to assess miscarriage rates. Metabolic outcomes, such as lipid and glucose profiles, will also be evaluated.
|Obese Overweight Miscarriage Recurrent Pregnancy Loss||Behavioral: Structured Weight Loss Program Behavioral: Routine Weight Loss Counseling|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Pregnancy Outcomes in Overweight and Obese Women With a History of Recurrent Pregnancy Loss Randomized to a Structured Weight Loss Program Versus Routine Weight-Loss Counseling: A Pilot Study|
- Term live birth rate [ Time Frame: 2.5 years ]
- Weight loss - goal for weight loss defined as 5 percent of enrollment body weight lost [ Time Frame: 6 months ]
- Changes in triglyceride levels [ Time Frame: 3 months ]
- Changes in high density lipoprotein levels [ Time Frame: 3 months ]
- Changes in alanine aminotransferase (ALT) levels [ Time Frame: 3 months ]
- Changes in fasting insulin levels [ Time Frame: 3 months ]
- Changes in postprandial insulin levels [ Time Frame: 3 months ]
- Changes in fasting glucose levels [ Time Frame: 3 months ]
- Changes in postprandial glucose levels [ Time Frame: 3 months ]
- Changes in hemoglobin A1c levels [ Time Frame: 3 months ]
|Study Start Date:||December 2010|
|Study Completion Date:||December 2013|
|Primary Completion Date:||December 2013 (Final data collection date for primary outcome measure)|
Experimental: Structured Weight Loss
Women randomized to this arm will meet with a registered dietician regularly for review of calorie recommendations and food diary. As well as regular clinic visits to measure patients weight.
Behavioral: Structured Weight Loss Program
Those patients randomized to the structured weight loss group will have a formal evaluation and counseling a medical endocrinologist specializing in weight management. The structured weight loss program will consist of meeting with a dietician who will guide them on following a hypocaloric diet with a calorie deficit of 750kcal/day. The weight loss goal will be to lose 1-1.5 pounds/week. The participants will receive teaching utilizing the American Diabetes Association Exchange Lists and will receive sample meal plans. In addition, participants will be seen by the dietitian once a week for a month, then every 2 weeks for 2 months, then once per month for 3 months. Patients randomized to the study group will continue in the structured weight loss program for 6 months.
Active Comparator: Routine Weight Loss Counseling
Patients are counseled by a physicians about the impact of maternal weight on fertility and pregnancy outcomes.
Behavioral: Routine Weight Loss Counseling
Participants randomized to the routine weight loss counseling group will receive the ACOG Patient Education pamphlets on obesity.
The purpose of this study is to investigate the impact of a structured weight loss program versus traditional weight-loss counseling on pregnancy outcomes in women with recurrent pregnancy loss. The study protocol is as follows:
- Patients will be notified of study via flyer inserted into patient chart at initial clinic visit, physician referral or Stanford website. Patients expressing interest will have their charts reviewed to confirm that they meet all enrollment criteria. Potential subjects will then be contacted via phone and verbal consent to participate obtained.
- The participant will then have an office visit for consent signing and randomization. A formal weight will be obtained, the Beck Depression Inventory will be administered by Penny Donnelly, a self-administered questionnaire will be completed, and a basic laboratory evaluation, including a fasting lipid panel, alanine aminotransferase (ALT), fasting glucose and insulin levels, 2-hour glucose tolerance test, hemoglobin A1c and CRP will be preformed.
- The patients will then be randomized to traditional weight loss counseling (control group) or to the structured weight loss program (study group). Patients will be instructed to discontinue attempts at conception.
- Those patients randomized to the control group will receive the ACOG Patient Education pamphlets on obesity.
- Those patients randomized to the study group will have a formal evaluation and counseling by Dr. Sun Kim, a medical endocrinologist specializing in weight management. They will then be enrolled in a structured weight loss program.
- For all patients, a 3-month follow-up office visit will be scheduled. At this visit, a formal weight will be obtained, the Beck Depression Inventory will be re-administered by Penny Donnelly, a self-administered questionnaire will be completed, and a follow-up laboratory evaluation, including a fasting lipid panel, alanine aminotransferase (ALT), fasting glucose and insulin levels, 2-hour glucose tolerance test, hemoglobin A1c and CRP will be preformed. Patients will be informed that they may now being attempts to conceive.
- Patients randomized to the study group will continue in the structured weight loss program for 6 months.
- Six months after enrollment, all patients will have a telephone interview in which a close-out questionnaire will be administered and a final, self-reported weight will be obtained.
- Primary and secondary outcomes will be followed for 2.5 years after date of enrollment for all patients.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01325805
|United States, California|
|Stanford University School of Medicine|
|Stanford, California, United States, 94305|
|Principal Investigator:||Ruth Bunker Lathi||Stanford University|